Important Notice from CHUGAI PHARMACEUTICAL

PICKUP CONTENTS

企業広告

Innovation Beyond Imagination - Chugai Brand Statement

Watch the video on our YouTube channel and discover how we're bringing "Innovation Beyond Immagination" to life.

（別ウィンドウで開く）

Chugai Pharmaceutical 100th Anniversary Site

We look back at Chugai's 100 years of contributing to patients and society through numerous innovations since its founding in 1925.

History of Chugai Pharmaceutical

Our founding spirit in 1925 was to "make drugs that benefit society."
Even after 100 years have passed, our founding commitment to "for patients" remains unchanged.

Advanced and sustainable patient-centric healthcare

Learn about Chugai's core values, which prioritize each patient’s wellbeing as our highest consideration in conducting our business.

ABOUT

We get to the future ahead of the disease.

Share of therapeutic antibody sales in Japan*1Copyright © 2025 IQVIA. Calculated based on JPM 2024. Reprinted with permission. The scope of the market is defined by Chugai.

No.1

Breakthrough Therapy Designations*2A system introduced in July 2012 by the U.S. Food and Drug Administration aimed at expediting the development and review of drugs for the treatment of severe or life-threatening diseases or symptoms.

9times

Innovative new drugs
as a percentage of sales*3Proportion of sales from products that qualify for premium pricing. (2024)

67%

Countries approving Chugai products

More than110

Operating profit growth after starting the strategic alliance with Roche (2002-2024)

21times higher

Chugai is a research and development-oriented pharmaceutical company with unique technology and science as its strengths. In collaboration with Roche, we are committed to continuously generating innovation with the aim of continuously providing patients with innovative drugs and services.

For those who want to know about
Chugai’s characteristics and strengths
What kind of company is Chugai Pharmaceutical?
For those who want to know more about
Chugai
About Chugai

  • *1 Copyright © 2025 IQVIA. Calculated based on JPM 2024. Reprinted with permission. The scope of the market is defined by Chugai.

  • *2 A system introduced in July 2012 by the U.S. Food and Drug Administration aimed at expediting the development and review of drugs for the treatment of severe or life-threatening diseases or symptoms.

  • *3 Proportion of sales from products that qualify for premium pricing. (2024)

The three key drivers driving Chugai's growth are RED*Research and Early Development Shift, DX, and open innovation.
We will shift our resources to discovery
research and early clinical development, which are the source of our value creation, apply digital technology to create innovative new drugs and increase efficiency in the value chain, and actively collaborate with external partners.

* Research and Early Development

The purpose of innovation, R&D efforts, and results

Innovation

SUSTAINABILITY

Putting sustainability at the heart of our business
Creating shared value with Society and developing together

We aim to lead solving social issues through our business activities, share the value created through these activities with our diverse stakeholders, and to grow together with society.

Chugai's Perspective on Social Issues and How to Solve Them

We aim to lead solving social issues through our business activities, share the value created through these activities with our diverse stakeholders, and to grow together with society.

Chugai's Perspective on Social Issues and How to Solve Them

Sponsoring the "Chugai Pharmaceutical 2025 Chair Ski Workshop for Parents and Children" Celebrating its 10th Anniversary

  • Social Contribution
  • Inclusive Society

Special Sponsorship of "Dance Class and Recital for Everyone"

  • Social Contribution
  • Inclusive Society

Report on the Survey Results of Vehicles Usage in Para-transit Vehicles Donation Program

  • Social Contribution
  • Social Welfare

Chugai Group Achieves 100% Renewable Energy for Electricity Procured at All Sites

  • Global Environment

Chugai Life Science Park Yokohama certified as a Natural Symbiosis Site by the Ministry of the Environment

  • Global Environment

Supporting the Cervical Cancer Elimination Program in Marshall Islands and Fiji

  • Sustainable Patient-Centric Healthcare
  • Global Health
  • Social Contribution

Elimination of cervical cancer and related morbidity and mortality in the context of Universal Health Coverage in Bhutan

  • Sustainable Patient-Centric Healthcare
  • Global Health
  • Social Contribution

The Fujieda Plant has received the Director-General of the Kanto Bureau of Economy, Trade, and Industry Award for Excellent Energy Management Businesses for FY 2024

  • Global Environment

View all Chugai activity reports

Activity Reports

Stories

Creating Continuous Innovation.
The Story of Our Challenges

  • #Digital Technology
  • #Open Innovation
  • #Co-Creation

CHUGAI INNOVATION DAY 2024 Report—More Than 3,000 in Attendance

Chugai Pharmaceutical’s CHUGAI INNOVATION DAY 2024 was hosted on November 25 (Mon) and 26 (Tue), 2024. This was the fifth hosting of the CHUGAI INNOVATIO

  • Innovation
  • R&D
  • DX
  • Event
  • #Sustainability

Corporate Growth Through Employee Health: Health and Productivity Management Alongside Employees to Create Platforms for Innovation and Working Environments for Peace of Mind

Chugai Pharmaceutical contributes to the health of people across the world through its innovative pharmaceuticals and services. Essential to fulfilling this mi

  • Sustainability
  • Human Resources
  • Health and Productivity Management
  • #Digital Technology
  • #Co-Creation

Takao Suzuki was previously an employee at Microsoft where he supported numerous companies as director of the DX strategy advisory department. He now works as Head of the DX Unit at Chugai Pharmaceutical. According to Suzuki, what are the key factors to ensuring the successful implementation of DX?

Aiming to become the top innovator in the healthcare industry, Chugai Pharmaceutical has positioned DX as a fundamental element of its growth strategy. Phase 1

  • Innovation
  • DX
  • CHUGAI DIGITAL VISION 2030
  • Top Interview
  • #Science and Technology
  • #Digital Technology
  • #Sustainability

Greater Efficiency in Bioprocess Development. Digital Transformations in Pharmaceuticals

Chugai Pharmaceutical is currently promoting companywide DX to achieve the targets of its new growth strategy Top I 2030. The company is focusing on innovative

  • Innovation
  • R&D
  • DX
  • Sustainability
  • CHUGAI DIGITAL VISION 2030
  • Production Technology
  • #Science and Technology

Working to Reform the Drug Discovery Process—Acceleration of Drug Discovery Research Using Cryo-EM

Torizawa is general manager of the Protein Science Research Department. He is currently in charge of the early stages of drug discovery to uncover molecules th

  • Innovation
  • R&D
  • Cryo-Electron Microscopy
  • #Science and Technology
  • #Digital Technology

Working Toward Greater Efficiency in the Drug Discovery Process for Mid-size Molecules. Development of a Crystallization Confirmation App Using Agile Development Methods

Agile development has recently been garnering attention as a method that involves quickly ascertaining needs and progressing with a project in an agile and fle

  • Innovation
  • R&D
  • DX
  • Mid-Molecule Pharmaceuticals
  • #Business Models
  • #Digital Technology

Supporting the transformation of business with global-standard systems infrastructure. Stories from behind the scenes of the ERP system renewal project and the sense of reward that it gives, as discussed by staff working on the next-generation core business (ERP) system

With the promotion of DX, expectations are growing for the appropriate use of information about companies’ management resources. At Chugai Pharmaceutical

  • R&D
  • DX
  • Recruitment
  • IT Infrastructure
  • #Business Models
  • #Digital Technology

Leading the optimization of ICT infrastructure. Making advanced solutions a strength in Chugai Pharmaceutical’s business transformation

Sasaki is a member of the IT Solution Department. As Group Manager of a group that is responsible for applications used in the R&D field, from introduction

  • DX
  • Recruitment
  • IT Infrastructure

Our employees want to bring happiness to our patients. Here are the thoughts of these employees and the stories of their challenges.

Read Chugai's culture

Stories

UPDATE

Latest Information

Notices What's new News

Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.